FATE THERAPEUTICS INC (FATE)
Biological Products, (No Diagnostic Substances)
Latest Price
$2.45
TTM P/E
--
Normalized P/E
--
Div Yield
--
Book Value
1.50
P/B Ratio
1.64
Institutional Ownership
56.8% held by institutions| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| Redmile Group, LLC | 12.87M | $15.0M | 11.07% | -- | 2026-03-31 |
| BlackRock, Inc. | 10.07M | $12.0M | 8.66% | -107.9K | 2026-03-31 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.19M | $5.0M | 3.61% | -- | 2026-03-31 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 4.13M | $4.0M | 3.56% | -- | 2026-03-31 |
| JOHNSON & JOHNSON | 3.38M | $4.0M | 2.91% | -- | 2026-03-31 |
| AQR CAPITAL MANAGEMENT LLC | 3.00M | $3.0M | 2.58% | +1.84M | 2026-03-31 |
| RENAISSANCE TECHNOLOGIES LLC | 2.97M | $3.0M | 2.56% | +613.8K | 2026-03-31 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.59M | $3.0M | 2.23% | +122.1K | 2026-03-31 |
| STATE STREET CORP | 2.26M | $2.0M | 1.95% | -2.0K | 2026-03-31 |
| UBS Group AG | 1.82M | $2.0M | 1.57% | +1.42M | 2026-03-31 |